A Study of EP0031 in Patients With Advanced RET-altered Malignancies
Phase 1/2
265
about 4.8 years
18+
18 sites in CA, DC, FL +11
What this study is about
Researchers are testing a treatment called EP0031 to see if it's safe and effective for people with advanced RET-altered cancers. The trial will help determine the best dose of this medication.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take EP0031
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Module A: Incidence of Dose-limiting Toxicity (DLTs ) during the first 28 days of EP0031 treatment, Modules B and C: Overall Response Rate (ORR) as measured using RECIST v1.1
Secondary: Area under the plasma concentration versus time curve (AUC), Maximum Plasma Concentration (Cmax), Time taken for drug concentration to fall from half its original value (Half-life)
Oncology